Key Points
- Director Joshua Ruch sold 38,000 shares on November 24 at an average price of $160.37 for proceeds of $6.09 million, cutting his holdings by 76.09% to 11,941 shares.
- GeneDx topped quarterly expectations with EPS of $0.49 vs. $0.28 forecast and revenue of $116.74 million vs. $104.33 million, reporting a return on equity of 20.22%.
- Analyst coverage is mixed but averages a Moderate Buy (avg. price target $129.22); the stock trades near its 1‑year high (~$165) and carries an unusually high P/E (~1,840), indicating elevated valuation and volatility.
GeneDx Holdings Corp. (NASDAQ:WGS - Get Free Report) Director Joshua Ruch sold 38,000 shares of GeneDx stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $160.37, for a total transaction of $6,094,060.00. Following the completion of the sale, the director owned 11,941 shares of the company's stock, valued at $1,914,978.17. This represents a 76.09% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
GeneDx Stock Performance
WGS stock opened at $165.61 on Thursday. The company has a debt-to-equity ratio of 0.18, a current ratio of 2.71 and a quick ratio of 2.59. GeneDx Holdings Corp. has a 1 year low of $55.17 and a 1 year high of $170.75. The company has a market cap of $4.79 billion, a P/E ratio of 1,840.11 and a beta of 2.01. The stock's fifty day moving average price is $129.31 and its 200-day moving average price is $106.00.
GeneDx (NASDAQ:WGS - Get Free Report) last posted its quarterly earnings data on Tuesday, October 28th. The company reported $0.49 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.28 by $0.21. GeneDx had a net margin of 0.52% and a return on equity of 20.22%. The company had revenue of $116.74 million for the quarter, compared to the consensus estimate of $104.33 million. GeneDx has set its FY 2025 guidance at EPS. On average, equities analysts forecast that GeneDx Holdings Corp. will post 0.97 earnings per share for the current year.
Analysts Set New Price Targets
Several brokerages recently issued reports on WGS. Zacks Research downgraded GeneDx from a "strong-buy" rating to a "hold" rating in a research note on Thursday, October 2nd. Weiss Ratings reaffirmed a "sell (d)" rating on shares of GeneDx in a report on Wednesday, October 8th. Wells Fargo & Company boosted their price objective on GeneDx from $95.00 to $140.00 and gave the stock an "equal weight" rating in a research note on Tuesday, November 4th. Guggenheim restated a "buy" rating and set a $170.00 price objective (up from $115.00) on shares of GeneDx in a research report on Wednesday, October 29th. Finally, BTIG Research lifted their target price on GeneDx from $140.00 to $165.00 and gave the stock a "buy" rating in a report on Wednesday, October 29th. Seven analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $129.22.
Read Our Latest Analysis on WGS
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in the stock. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in GeneDx by 5.1% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,702 shares of the company's stock valued at $399,000 after buying an additional 181 shares during the period. Jones Financial Companies Lllp raised its stake in shares of GeneDx by 664.3% during the third quarter. Jones Financial Companies Lllp now owns 214 shares of the company's stock valued at $25,000 after acquiring an additional 186 shares in the last quarter. Quarry LP boosted its holdings in shares of GeneDx by 248.8% in the third quarter. Quarry LP now owns 293 shares of the company's stock valued at $32,000 after purchasing an additional 209 shares during the period. Chung Wu Investment Group LLC boosted its holdings in shares of GeneDx by 8.2% in the second quarter. Chung Wu Investment Group LLC now owns 3,300 shares of the company's stock valued at $305,000 after purchasing an additional 250 shares during the period. Finally, Kovack Advisors Inc. grew its stake in GeneDx by 14.3% in the third quarter. Kovack Advisors Inc. now owns 2,868 shares of the company's stock worth $309,000 after purchasing an additional 358 shares in the last quarter. 61.72% of the stock is currently owned by institutional investors.
About GeneDx
(
Get Free Report)
GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
